ANZCTR - Registration

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers

Trial registered on ANZCTR

Registration number

ACTRN12618000238279

Ethics application status

Approved

Date submitted

1/02/2018

Date registered

14/02/2018

Date last updated

24/04/2020

Date data sharing statement initially provided

18/03/2019

Type of registration

Prospectively registered

Titles & IDs

Public title

The effect of supplementation with a mitochondrial-targeted antioxidant (MitoQ) on training induced adaptations and sport performance in healthy adult males.

Scientific title

The effect of MitoQ(TM) supplementation on muscle biomarkers and sport performance in healthy adult males.

Secondary ID [1]

Nil known

Universal Trial Number (UTN)

U1111-1201-8005

Trial acronym

Linked study record

Health condition

Health condition(s) or problem(s) studied:

mitochondrial function

Condition category

Condition code

Musculoskeletal

Normal musculoskeletal and cartilage development and function

Intervention/exposure

Study type

Interventional

Description of intervention(s) / exposure

The study contains two arms; treatment (Arm 1) and placebo (Arm 2). Participants in Arm 1 will be asked to consume one MitoQ oral capsule (containing mitoquinol mesylate equivalent to 20mg mitoquinol) per day for 5 weeks. Adherence to the supplement protocol will be monitored via tablet return.

Participants in both arms will undergo high intensity interval exercise training. Participants will be asked to come to the University of Auckland Grafton campus to complete 10 face-to-face training sessions over a period of 3 weeks, which will be supervised by the researcher. During the first week participants will complete 3 sessions of 8 repeated 60s intervals of high-intensity stationary cycling (at 100% peak power output determined from VO2max test) with 75 s of recovery between each repetition .Training sessions in the first week are expected to last around 30 minutes, including a 5 minute warm-up and 5 minute cool down. During the second week participants will complete 3 sessions of 10 repeated 60s intervals of high-intensity stationary cycling (at 100% peak power output determined from VO2max test) with 75 s of recovery between each repetition. Training sessions in the second week are expected to last around 35 minutes, including a 5 minute warm-up and 5 minute cool down. During the third week participants will complete 4 sessions of 12 repeated 60 s intervals of high-intensity stationary cycling (at 100% peak power output determined from VO2max test) with 75 s of recovery between each repetition. Training sessions in the third week are expected to last around 40 minutes, including a 5 minute warm-up and 5 minute cool down. Training sessions will be separated by at least one day and no more than 4 days,

Intervention code [1]

Treatment: Other

Comparator / control treatment

Participants in the control group will be asked to consume one oral capsule per day for 5 weeks. Placebo control will be identical capsules containing inert, edible powder (cornstarch).

Control group

Placebo

Outcomes

Primary outcome [1]

The effect of MitoQ supplementation on exercise performance measured by change in time to complete a 500 kj work trial on a stationary cycle ergometer

Timepoint [1]